[1]
|
Hanna, N., Shepherd, F.A., Fossella, F.V., Pereira, J.R., De Marinis, F., von Pawel, J., et al. (2004) Randomized Phase III Trial of Pemetrexed versus Doeetaxel in Patients with Non-Small-Cell Lung Cancer Previously Treated with Chemotherapy. Journal of Clinical Oncology, 22, 1589-1597.
https://doi.org/10.1200/JCO.2004.08.163
|
[2]
|
Di Maio, M., Perrone, F., Chiodini, P., Gallo, C., Camps, C., Schuette, W., et al. (2007) Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared with Once Every Week Second-Line Treatment of Advancednon-Small-cell Lung Cancer. Journal of Clinical Oncology, 25, 1377-1382.
https://doi.org/10.1200/JCO.2006.09.8251
|
[3]
|
Peterson, P., Park, K., Fossella, F., Gatzemeier, U., John, W. and Scagliotti, G.V. (2007) Is Pemetrexed More Effective in Adenocarcinoma and Large Cell Lung Cancer than in Squamous Cell Carcinoma? A Retrospective Analysis of a Phase III Trial of Pemetrexed vs. Docetaxel in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2, s851.
https://doi.org/10.1097/01.JTO.0000284677.33344.62
|
[4]
|
Al-Farsi, A. and Ellis, P.M. (2014) Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line. Frontiersin Oncology, 4, 157. https://doi.org/10.3389/fonc.2014.00157
|
[5]
|
Gatzemeier, U., von Pawel, J., Gottfried, M., ten Velde, G.P., Mattson, K., de Marinis, F., et al. (2000) Phase III Comparative Study of High-Dose Cisplatin versus a Combination of Paclitaxel and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Clinical Oncology, 18, 3390-3399.
https://doi.org/10.1200/JCO.2000.18.19.3390
|
[6]
|
Scagliotti, G.V., De Marinis, F., Rinaldi, M., Crino, L., Gridelli, C., Ricci, S., et al. (2002) Italian Lung Cancer Project: Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 20, 4285-4291. https://doi.org/10.1200/JCO.2002.02.068
|
[7]
|
Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J., et al. (2002) Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 346, 92-98.
https://doi.org/10.1056/NEJMoa011954
|
[8]
|
Shepherd, F.A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O’Rourke, M., et al. (2000) Prospective Randomized Trial of Docetaxel versus Best Supportive Care in Patients with Non-Small-Cell Lung Cancer Previously Treated with Platinum Based Chemotherapy. Journal of Clinical Oncology, 18, 2095-2103.
https://doi.org/10.1200/JCO.2000.18.10.2095
|
[9]
|
Fossella, F.V., DeVore, R., Kerr, R.N., Crawford, J., Natale, R.R., Dunphy, F., et al. (2000) Randomized Phase III Trial of Docetaxel versus Vinorelbine or Ifosfamide in Patients with Advanced Non-Small-Cell Lung Cancer Previously Treated with Platinum-Containing Chemotherapy Regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. Journal of Clinical Oncology, 18, 2354-2362.
https://doi.org/10.1200/JCO.2000.18.12.2354
|
[10]
|
Scagliotti, G.V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., et al. (2008) Phase III Study Comparing Cisplatin plus Gemcitabine with Cisplatin plus Pemetrexed in Chemotherapy-Naive Patients with Advanced-Stage Nonsmall-Cell Lung Cancer. Journal of Clinical Oncology, 26, 3543-3551.
https://doi.org/10.1200/JCO.2007.15.0375
|
[11]
|
Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., et al. (2009) The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies. Oncologist, 14, 253-263.
https://doi.org/10.1634/theoncologist.2008-0232
|
[12]
|
Wang, L.N., Wang, Y., Guan, Q., Liu, Y., He, T.Y. and Wang, J.R. (2016) Establishment of a first-line second-line Treatment Model for Human Pulmonary Adenocarcinoma. Oncology Letters, 12, 4461-4466. https://doi.org/10.3892/ol.2016.5299
|
[13]
|
Liu, Y.-P., Ling, Y., Qi, Q.-F., Zhang, Y.-P., Zhang, C.-S., Zhu, C.-T., et al. (2013) The Effects of ERCC1 Expression Levels on the Chemosensitivity of Gastric Cancer Cells to Platinum Agents and Survival in Gastric Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy. Oncology Letters, 5, 935-942.
https://doi.org/10.3892/ol.2012.1096
|
[14]
|
Cai, Y., Yan, X., Zhang, G.Q., Zhao, W.H. and Jiao, S.C. (2015) The Predictive Value of ERCC1 and p53 for the Effect of Panobinostat and Cisplatin Combination Treatment in NSCLC. Oncotarget, 6, 18997-19005.
https://doi.org/10.18632/oncotarget.3620
|
[15]
|
Huggins, D.J., Venkitaraman, A.R. and Spring, D.R. (2011) Rational Methods for the Selection of Diverse Screening Compounds. ACS Chemical Biology, 6, 208-217.
https://doi.org/10.1021/cb100420r
|
[16]
|
Cragg, G.M. and Newman, D.J. (2013) Natural Products: A Continuing Source of Novel Drug Leads. Biochimica et Biophysica Acta, 1830, 3670-3695.
https://doi.org/10.1016/j.bbagen.2013.02.008
|
[17]
|
Kennedy, J.P., Williams, L., Bridges, T.M., Daniels, R.N., Weaver, D. and Lindsley, C.W. (2008) Application of Combinatorial Chemistry Science on Modern Drug Discovery. Journal of Combinatorial Chemistry, 10, 345-354.
https://doi.org/10.1021/cc700187t
|
[18]
|
Corbi-Verge, C. and Kim, P.M. (2016) Motif Mediated Protein-Protein Interactions as Drug Targets. Cell Communication and Signaling, 14, 8.
https://doi.org/10.1186/s12964-016-0131-4
|
[19]
|
Hao, H., Maeda, Y., Fukazawa, T., Yamatsuji, T., Takaoka, M., Bao, X.H., et al. (2013) Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer. PLoS ONE, 8, e71093.
https://doi.org/10.1371/journal.pone.0071093
|
[20]
|
Newman, D.J. and Cragg, G.M. (2004) Marine Natural Products and Related Compounds in Clinical and Advanced Preclinical Trials. Journal of Natural Products, 67, 1216-1238. https://doi.org/10.1021/np040031y
|
[21]
|
Tavassoli, A. (2017) SICLOPPS Cyclic Peptide Libraries in Drug Discovery. Current Opinion in Chemical Biology, 38, 30-35. https://doi.org/10.1016/j.cbpa.2017.02.016
|
[22]
|
Perera, Y., Toro, N.D., Gorovaya, L., Fernandez-DE-Cossio, J., Farina, H.G. and Perea, S.E. (2014) Synergistic Interactions of the Anti-Casein Kinase 2 CIGB-300 Peptide and Chemotherapeutic Agents in Lung and Cervical Preclinical Cancer Models. Molecular and Clinical Oncology, 2, 935-944.
https://doi.org/10.3892/mco.2014.338
|
[23]
|
Dantas-Barbosa, C., de Macedo Brigido, M. and Maranhao, A.Q. (2012) Antibody Phage Display Libraries: Contributions to Oncology. International Journal of Molecular Sciences, 13, 5420-5240. https://doi.org/10.3390/ijms13055420
|
[24]
|
Thatcher, N., Hirsch, F.R., Luft, A.V., Szczesna, A., Ciuleanu, T.E., Dediu, M., et al. (2015) Necitumumab plus Gemcitabine and Cisplatin versus Gemcitabine and Cisplatin Alone as First-Line Therapy in Patients with Stage IV Squamous Non-Small-Cell Lung Cancer (SQUIRE): An Open-Label, Randomised, Controlled Phase 3 Trial. Lancet Oncology, 16, 763-774. https://doi.org/10.1016/S1470-2045(15)00021-2
|
[25]
|
Sittampalam, G.S., Kahl, S.D. and Janzen, W.P. (1997) High-Throughput Screening: Advances in Assay Technologies. Current Opinion in Chemical Biology, 1, 384-391.
https://doi.org/10.1016/S1367-5931(97)80078-6
|
[26]
|
Silverman, L., Campbell, R. and Broach, J.R. (1998) New Assay Technologies for High-Throughput Screening. Current Opinion in Chemical Biology, 2, 397-403.
https://doi.org/10.1016/S1367-5931(98)80015-X
|
[27]
|
Bennett, D.C., Charest, J., Sebolt, K., Lehrman, M., Rehemtulla, A. and Contessa, J.N. (2013) High-Throughput Screening Identifies Aclacinomycin as a Radiosensitizer of EGFR-Mutant Non-Small Cell Lung Cancer. Translational Oncology, 6, 382-391. https://doi.org/10.1593/tlo.13232
|
[28]
|
Singh, S., Carpenter, A.E. and Genovesio, A. (2014) Increasing the Content of High-Content Screening: An Overview. Journal of Biomolecular Screening, 19, 640-650. https://doi.org/10.1177/1087057114528537
|
[29]
|
Xia, X., Yang, J., Li, F., Li, Y., Zhou, X., Dai, Y., et al. (2010) Image-Based Chemical Screening Identifies Drug Efflux Inhibitors in Lung Cancer Cells. Cancer Research, 70, 7723-7733. https://doi.org/10.1158/0008-5472.CAN-09-4360
|
[30]
|
Lin, S.H., Zhang, J., Giri, U., Stephan, C., Sobieski, M., Zhong, L., et al. (2014) A High Content Clonogenic Survival Drug Screen Identifies Mek Inhibitors as Potent Radiation Sensitizers for KRAS Mutant Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 9, 965-973. https://doi.org/10.1097/JTO.0000000000000199
|
[31]
|
Shepherd, C.A., Hopkins, A.L. and Navratilova, I. (2014) Fragment Screening by SPR and Advanced Application to GPCRs. Progress in Biophysics & Molecular Biology, 116, 113-123. https://doi.org/10.1016/j.pbiomolbio.2014.09.008
|
[32]
|
Nguyen, H.H., Park, J., Kang, S. and Kim, M. (2015) Surface Plasmon Resonance: A Versatile Technique for Biosensor Applications. Sensors, 15, 10481-10510.
https://doi.org/10.3390/s150510481
|
[33]
|
Blangy, A. and Fort, P. (2012) Using a Modified Yeast Two-Hybrid System to Screen for Chemical GEF Inhibitors. Methods in Molecular Biology, 928, 81-95.
https://doi.org/10.1007/978-1-62703-008-3_7
|
[34]
|
Ohashi, K., Rai, K., Fujiwara, Y., Osawa, M., Hirano, S., Takata, K., et al. (2008) Induction of Lung Adenocarcinoma in Transgenic Mice Expressing Activated EGFR Driven by the SP-C Promoter. Cancer Science, 99, 1747-1753.
https://doi.org/10.1111/j.1349-7006.2008.00875.x
|
[35]
|
Qu, Z., Sun, F., Zhou, J., Li, L., Shapiro, S.D. and Xiao, G. (2015) Interleukin-6 Prevents the Initiation But Enhances the Progression of Lung Cancer. Cancer Research, 75, 3209-3215. https://doi.org/10.1158/0008-5472.CAN-14-3042
|
[36]
|
Memon, A.A., Jakobsen, S., Dagnaes-Hansen, F., Sorensen, B.S., Keiding, S. and Nexo, E. (2009) Positron Emission Tomography (PET) Imaging with [11C]-Labeled Erlotinib: A Micro-PET Study on Mice with Lung Tumor Xenografts. Cancer Research, 69, 873-878. https://doi.org/10.1158/0008-5472.CAN-08-3118
|
[37]
|
Steiner, P., Joynes, C., Bassi, R., Wang, S., Tonra, J.R., Hadari, Y.R., et al. (2007) Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non-Small Cell Lung Cancer Xenografts Expressing Wild-Type and Mutated Epidermal Growth Factor Receptor. Clinical Cancer Research, 13, 1540-1551.
https://doi.org/10.1158/1078-0432.CCR-06-1887
|
[38]
|
Kellar, A., Egan, C. and Morris, D. (2015) Preclinical Murine Models for Lung Cancer: Clinical Trial Applications. Biomed Research International, 2015, Article ID: 621324. https://doi.org/10.1155/2015/621324
|
[39]
|
Fichtner, I., Rolff, J., Soong, R., Hoffmann, J., Hammer, S., Sommer, A., et al. (2008) Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers. Clinical Cancer Research, 14, 6456-6468. https://doi.org/10.1158/1078-0432.CCR-08-0138
|
[40]
|
Merk, J., Rolff, J., Becker, M., Leschber, G. and Fichtner, I. (2009) Patient-Derived Xenografts of Non-Small-Cell Lung Cancer: A Pre-Clinical Model to Evaluate Adjuvant Chemotherapy? European Journal of Cardiothoracic Surgery, 36, 454-459.
https://doi.org/10.1016/j.ejcts.2009.03.054
|
[41]
|
Dong, X., Guan, J., English, J.C., Flint, J., Yee, J., Evans, K., et al. (2010) Patient-Derived First Generation Xenografts of Non-Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy. Clinical Cancer Research, 16, 1442-1451. https://doi.org/10.1158/1078-0432.CCR-09-2878
|
[42]
|
Quéré, G., Descourt, R., Robinet, G., Autret, S., Raguenes, O., Fercot, B., et al. (2016) Mutational Status of Synchronous and Metachronous Tumor Samples in Patients with Metastatic Non-Small-Cell Lung Cancer. BMC Cancer, 16, 210.
https://doi.org/10.1186/s12885-016-2249-6
|
[43]
|
Roviello, G. (2015) The Distinctive Nature of Adenocarcinoma of the Lung. OncoTargets and Therapy, 8, 2399-2406. https://doi.org/10.2147/OTT.S89225
|
[44]
|
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., et al. (2009) Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. New England Journal of Medicine, 361, 958-967.
https://doi.org/10.1056/NEJMoa0904554
|
[45]
|
Shi, Y., Li, J., Zhang, S., Wang, M., Yang, S., Li, N., et al. (2015) Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology Mainland China Subset Analysis of the PIONEER Study. PLoS ONE, 10, e0143515.
https://doi.org/10.1371/journal.pone.0143515
|
[46]
|
Que, D., Xiao, H., Zhao, B., Zhang, X., Wang, Q., Xiao, H., et al. (2016) EGFR Mutation Status in Plasma and Tumor Tissues in Non-Small Cell Lung Cancer Serves as a Predictor of Response to EGFR-TKI Treatment. Cancer Biology & Therapy, 17, 320-327. https://doi.org/10.1080/15384047.2016.1139238
|
[47]
|
Cappuzzo, F., Janne, P.A., Skokan, M., Finocchiaro, G., Rossi, E., Ligorio, C., et al. (2009) MET Increased Gene Copy Number and Primary Resistance to Gefitinib Therapy in Non-Small-Cell Lung Cancer Patients. Annals of Oncology, 20, 298-304.
https://doi.org/10.1093/annonc/mdn635
|
[48]
|
Presta, L.G., Chen, H., O’Connor, S.J., Chisholm, V., Meng, Y.G., Krummen, L., et al. (1997) Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders. Cancer Research, 57, 4593-4599.
|
[49]
|
Cooper, M.R., Binkowski, C., Hartung, J. and Towle, J. (2016) Profile of Ramucirumab in the Treatment of Metastatic Non-Small-Cell Lung Cancer. OncoTargets Therapy, 9, 1953-1960. https://doi.org/10.2147/OTT.S80239
|
[50]
|
Johnson, D.H., Fehrenbacher, L., Novotny, W.F., Herbst, R.S., Nemunaitis, J.J., Jablons, D.M., et al. (2004) Randomized Phase II Trial Comparing Bevacizumab plus Carboplatin and Paclitaxel with Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 22, 2184-2191. https://doi.org/10.1200/JCO.2004.11.022
|